WFG Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

WFG Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$2K	Hold	44	–	–	﹤0.01%	1412
2017 Q1	$1K	Hold	44	–	–	﹤0.01%	1395
2016 Q4	$1K	Hold	44	–	–	﹤0.01%	1473
2016 Q3	$1K	Hold	44	–	–	﹤0.01%	1466
2016 Q2	$1K	Hold	44	–	–	﹤0.01%	1449
2016 Q1	$1K	Hold	44	–	–	﹤0.01%	1409
2015 Q4	$1K	Hold	44	–	–	﹤0.01%	1446
2015 Q3	$2K	Buy	+44	New	+$1.89K	﹤0.01%	1400

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

WFG Advisors's ENTA Position: Q2 2017 in Review

WFG Advisors held its Enanta Pharmaceuticals (ENTA) position steady in Q2 2017 at 44 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1412.

WFG Advisors first reported a position in ENTA in Q3 2015 and has held it in 8 quarters since. 122 funds tracked by Wall St. Rank hold ENTA as of Q2 2017.

WFG Advisors held 44 shares of Enanta Pharmaceuticals worth $2K as of Q2 2017.
WFG Advisors left its Enanta Pharmaceuticals share count unchanged in Q2 2017.
Enanta Pharmaceuticals made up ﹤0.01% of WFG Advisors's portfolio in Q2 2017, its #1412 holding.
WFG Advisors first reported a position in Enanta Pharmaceuticals in Q3 2015 and has held it in 8 quarters since.
122 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.